BNP Paribas Financial Markets’s Voyager Therapeutics VYGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $176K | Sell |
50,189
-15,064
| -23% | -$57.1K | ﹤0.01% | 4295 |
|
|
2026
Q1 | $252K | Buy |
65,253
+1,058
| +2% | +$4.17K | ﹤0.01% | 3954 |
|
|
2025
Q4 | $252K | Buy |
64,195
+21,856
| +52% | +$96.7K | ﹤0.01% | 3951 |
|
|
2025
Q3 | $198K | Buy |
42,339
+36,928
| +682% | +$134K | ﹤0.01% | 4017 |
|
|
2025
Q2 | $16.8K | Sell |
5,411
-41,965
| -89% | -$135K | ﹤0.01% | 4673 |
|
|
2025
Q1 | $160K | Buy |
47,376
+41,351
| +686% | +$193K | ﹤0.01% | 3827 |
|
|
2024
Q4 | $34.2K | Sell |
6,025
-43,210
| -88% | -$279K | ﹤0.01% | 4569 |
|
|
2024
Q3 | $288K | Buy |
49,235
+11,516
| +31% | +$83.7K | ﹤0.01% | 3093 |
|
|
2024
Q2 | $298K | Sell |
37,719
-11,050
| -23% | -$92.6K | ﹤0.01% | 2933 |
|
|
2024
Q1 | $454K | Buy |
48,769
+32,437
| +199% | +$274K | ﹤0.01% | 2891 |
|
|
2023
Q4 | $138K | Sell |
16,332
-3,750
| -19% | -$27.2K | ﹤0.01% | 3324 |
|
|
2023
Q3 | $156K | Buy |
20,082
+11,738
| +141% | +$107K | ﹤0.01% | 3189 |
|
|
2023
Q2 | $95.5K | Buy |
8,344
+8,276
| +12,171% | +$85.6K | ﹤0.01% | 3267 |
|
|
2023
Q1 | $524 | Hold |
68
| – | – | ﹤0.01% | 3718 |
|
|
2022
Q4 | $415 | Hold |
68
| – | – | ﹤0.01% | 3881 |
|
|
2022
Q3 | $403 | Sell |
68
-86
| -56% | -$551 | ﹤0.01% | 4547 |
|
|
2022
Q2 | $910 | Sell |
154
-15
| -9% | -$101 | ﹤0.01% | 3913 |
|
|
2022
Q1 | $1.29K | Hold |
169
| – | – | ﹤0.01% | 3941 |
|
|
2021
Q4 | $458 | Hold |
169
| – | – | ﹤0.01% | 4117 |
|
|
2021
Q3 | $444 | Buy |
169
+85
| +101% | +$276 | ﹤0.01% | 3928 |
|
|
2021
Q2 | $347 | Sell |
84
-4,603
| -98% | -$20.9K | ﹤0.01% | 3985 |
|
|
2021
Q1 | $22.1K | Sell |
4,687
-1,961
| -29% | -$13.4K | ﹤0.01% | 3744 |
|
|
2020
Q4 | $47.5K | Buy |
6,648
+490
| +8% | +$4.71K | ﹤0.01% | 3575 |
|
|
2020
Q3 | $65.7K | Buy |
6,158
+2,875
| +88% | +$33.7K | ﹤0.01% | 3337 |
|
|
2020
Q2 | $41.4K | Sell |
3,283
-12,149
| -79% | -$141K | ﹤0.01% | 3126 |
|
|
2020
Q1 | $141K | Buy |
15,432
+12,648
| +454% | +$145K | ﹤0.01% | 3041 |
|
|
2019
Q4 | $38.8K | Sell |
2,784
-755
| -21% | -$11K | ﹤0.01% | 3778 |
|
|
2019
Q3 | $60.9K | Buy |
3,539
+1,143
| +48% | +$24K | ﹤0.01% | 3371 |
|
|
2019
Q2 | $65.2K | Sell |
2,396
-2,096
| -47% | -$48K | ﹤0.01% | 3265 |
|
|
2019
Q1 | $86K | Buy |
4,492
+4,486
| +74,767% | +$58.4K | ﹤0.01% | 3217 |
|
|
2018
Q4 | $56 | Sell |
6
-705
| -99% | -$9.05K | ﹤0.01% | 4246 |
|
|
2018
Q3 | $13.5K | Hold |
711
| – | – | ﹤0.01% | 3608 |
|
|
2018
Q2 | $13.9K | Sell |
711
-2,731
| -79% | -$54K | ﹤0.01% | 3643 |
|
|
2018
Q1 | $64.7K | Sell |
3,442
-538
| -14% | -$11.6K | ﹤0.01% | 3412 |
|
|
2017
Q4 | $66.1K | Buy |
3,980
+2,937
| +282% | +$50.4K | ﹤0.01% | 3520 |
|
|
2017
Q3 | $21.5K | Sell |
1,043
-59
| -5% | -$666 | ﹤0.01% | 3559 |
|
|
2017
Q2 | $9.87K | Buy |
1,102
+1,100
| +55,000% | +$11.1K | ﹤0.01% | 3948 |
|
|
2017
Q1 | $26 | Sell |
2
-109
| -98% | -$1.32K | ﹤0.01% | 4042 |
|
|
2016
Q4 | $1.41K | Sell |
111
-684
| -86% | -$8.79K | ﹤0.01% | 3981 |
|
|
2016
Q3 | $9.55K | Buy |
795
+229
| +40% | +$3.1K | ﹤0.01% | 3183 |
|
|
2016
Q2 | $6.22K | Buy |
566
+472
| +502% | +$5.78K | ﹤0.01% | 3162 |
|
|
2016
Q1 | $821 | Sell |
94
-956
| -91% | -$10.8K | ﹤0.01% | 2523 |
|
|
2015
Q4 | $23K | Buy |
+1,050
| New | +$24.2K | ﹤0.01% | 3237 |
|
Other funds holding VYGR
AC
BNP Paribas Financial Markets's VYGR Position: Q2 2026 in Review
BNP Paribas Financial Markets reduced its Voyager Therapeutics (VYGR) stake by 23% in Q2 2026, selling an estimated $57.1K and leaving 50,189 shares worth $176K. The position accounts for ﹤0.01% of the portfolio, ranked #4295.
BNP Paribas Financial Markets first reported a position in VYGR in Q4 2015 and has held it in 43 quarters since. The position peaked at $454K in Q1 2024. 128 funds tracked by Wall St. Rank hold VYGR as of Q2 2026.
- BNP Paribas Financial Markets held 50,189 shares of Voyager Therapeutics worth $176K as of Q2 2026.
- BNP Paribas Financial Markets sold 15,064 Voyager Therapeutics shares in Q2 2026, an estimated $57.1K.
- Voyager Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #4295 holding.
- BNP Paribas Financial Markets first reported a position in Voyager Therapeutics in Q4 2015 and has held it in 43 quarters since.
- BNP Paribas Financial Markets's Voyager Therapeutics position peaked at $454K in Q1 2024.
- 128 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2026.
Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.